2023
|
In January 2023, Panacea Biotec donated 125,000 doses of Easy-five TT, which is a fully liquid
Pentavalent vaccine to Ministry of Health, Republic of Cuba for use in the National Health System.
|
2022
|
In October 2022, UNICEF and the Pan American Health Organization (PAHO) awarded Panacea Biotec
long-term supply contracts totalling US$ 127.30 million for the provision of its WHO-prequalified
fully liquid Pentavalent vaccination, Easyfive-TT® (DTwP-HepB-Hib).
In February 2022, Panacea Biotec sold its domestic formulations business to Mankind Pharma for Rs.
1,908 crore (US$ 252.85 million).
In February 2022, CEPI, THSTI, and Panacea Biotec partnered to develop broadly protective
Betacoronavirus vaccines.
|
2021
|
In September 2021, Panacea Biotec Limited exported the first shipment of the second dose of the
Sputnik V vaccine in India.
In May 2021, Panacea Biotec Limited started domestic production of Russia’s Sputnik V vaccine
to combat coronavirus
|
2020
|
Panacea Biotec announced successful completion of Phase I/II study of its novel, Tetravalent
recombinant chimeric Dengue candidate vaccine, DengiAll
Panacea Biotec and Refana collaborate to develop COVID-19 vaccine
Panacea transfers pharmaceuticals business to its wholly owned subsidiary ‘Panacea Biotec
Pharma Limited’
|
2019
|
Launched ViLACT to treat uncontrolled Type-2 Diabetes Mellitus patients IndiaRF announced
investment worth US$ 144million in Panacea Biotec
|
2018
|
Partnered with Serum Institute of India to expand market access for the world's first fully liquid
wP-based hexavalent vaccine, EasySix. It vaccinates children against DTwP, Hib, Hep. B and
Polio Inked tripartite agreement with Natco Pharma Limited and Breckenridge Pharmaceuticals
Inc. to manufacture and supply of Azacitidine injection in the US market
|
2017
|
Panacea Biotec announced acceptance of its abbreviated new drug application (ANDA) for paclitaxel
protein bound particles by the US FDA Partnered with Technology Development Board (TDB), Govt.
of India, regarding financial assistance for development and commercialisation of Dengue Tetravalent
Vaccine
|
2014
|
Partnered with a leading pharmaceutical company (name undisclosed) to develop and supply an
immunosuppressant generic product in the US
|
2013
|
Received WHO PQ for EasyFive TT
|
2012
|
Partnered with Kremers Urban for 11 High Barrier to Entry Generics and launched Tacrolimus Capsules
in the US
|
2007
|
Partnered with Punjab University to develop new chemical entities Signed an agreement with
Family Vaccines to supply combination vaccines in the Philippines Launched seven anti-cancer
products, manufactured by a Mumbai-based company and sold under the brand name of Panacea Biotec
|
2006
|
Panacea Biotec partnered with Nederlands Vaccine Instituut under which the latter would supply bulk
Inactivated Polio Vaccines (IPV), which will be used by the company in the manufacture of finished
IPV and several IPV based combination vaccines Collaborated with national research development
corporation for technology transfer of foot and mouth disease vaccine, developed by Indian
Veterinary Research Institute
|
2004
|
Collaborated with Cambridge Bio-stability, the UK, for thermo stable vaccines Marketing Joint
Venture with Chiron (now Novartis) Vaccines, the UK
|
2002
|
Recombinant vaccine production plant was commissioned
|
2001
|
Collaborated with a European MNC for R&D
|
1995
|
Established State -of the- art drug delivery R&D centre at Lalru
|
1993
|
Panacea Biotec Ltd. was formed with the merger of Panacea Drugs (P) Ltd. & Radicura Pharma
|
1988
|
Established a plant to produce vaccines at New Delhi, under the name of Radicura Pharma
|